Enfermedad pulmonar intersticial asociada a esclerosis sistémica (EPI-ES)

 

Effect of nintedanib in patients with systemic sclerosis‑associated interstitial lung disease and risk factors for rapid decline in forced vital capacity: further analyses of the SENSCIS trial

Khanna D et al.
 

Acceder

Efficacy and safety of nintedanib in patients with systemic sclerosis‑associated ILD (SSc‑ILD) and differing comorbidity burden: subgroup analyses of the SENSCIS trial

Highland KB et al.
 

Acceder

Effect of nintedanib on KL‑6 in patients with systemic sclerosis‑associated interstitial lung disease in the SENSCIS trial

Assassi S et al.

 

Acceder

 

Esophageal involvement and gastroesophageal reflux disease in patients with SSc‑ILD: data from a sub‑study of the SENSCIS trial

Kreuter M et al.

 

Acceder

Continued treatment with nintedanib in patients with systemic sclerosis‑associated interstitial lung disease (SSc‑ILD): two‑year data from SENSCIS‑ON

Allanore Y et al.
 

Acceder

Severity and impact of gastrointestinal symptoms in patients with SSc‑ILD treated with nintedanib: data from SENSCIS‑ON

Khanna D et al.

 

Acceder

 

SC-ES-08021